Want to see JP:2370 full AI Analyst Report?
2370 Stock Chart & Stats
¥29.00
-¥1.00(-2.70%)
At close: 4:00 PM EST
¥29.00
-¥1.00(-2.70%)
Day’s Range― - ―
52-Week Range¥23.00 - ¥43.00
Previous CloseN/A
Volume258.10K
Average Volume (3M)1.57M
Market Cap
¥6.76B
Enterprise Value¥4.04B
Total Cash (Recent Filing)¥5.03B
Total Debt (Recent Filing)¥91.32M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.29
Shares Outstanding281,667,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.11
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line growth (FY2025 +11.8%) indicates sustained demand for the company’s services. For a services firm in clinical research support, recurring project revenues and expanding client activity can underpin multi-quarter revenue resilience and room to scale fixed-cost leverage over time.
Low LeverageA conservatively levered balance sheet with effectively no debt materially reduces near-term solvency risk and preserves financing flexibility. This structural strength gives the company runway to fund operations, restructure, or raise capital without immediate servicing pressure amid operational turnarounds.
Clinical Research Service FocusOperating in healthcare/biotech support and clinical research services exposes the company to structural industry demand for trial and research support. Such businesses often have durable contract flows and specialized expertise, which can create steady long-term revenue opportunities when execution stabilizes.
Bears Say
Severe Net LossesVery large net losses and deeply negative margins are a durable operating weakness: they erode retained capital, reduce reinvestment ability, and limit strategic options. Persistently negative profitability impairs competitiveness and increases reliance on external funding if not corrected.
Worsening Free Cash FlowSharp deterioration in free cash flow shows losses are translating into real cash burn, not just accounting losses. Negative operating and free cash flow persist, heightening funding risk, shrinking liquidity cushions, and forcing potential dilutive financing or cutbacks that impair long‑term growth.
Margin Erosion & Equity DeclineA multi-year decline in gross margins alongside meaningful erosion of shareholder equity signals structural profitability problems. Lower gross margins compress long-term operating leverage and declining equity reduces balance sheet resilience, limiting capacity to absorb shocks or invest for growth.
MEDINET Co., Ltd. News
2370 FAQ
What was MEDINET Co., Ltd.’s price range in the past 12 months?
MEDINET Co., Ltd. lowest stock price was ¥23.00 and its highest was ¥43.00 in the past 12 months.
What is MEDINET Co., Ltd.’s market cap?
MEDINET Co., Ltd.’s market cap is ¥6.76B.
When is MEDINET Co., Ltd.’s upcoming earnings report date?
MEDINET Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were MEDINET Co., Ltd.’s earnings last quarter?
MEDINET Co., Ltd. released its earnings results on May 13, 2026. The company reported -¥0.78 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.78.
Is MEDINET Co., Ltd. overvalued?
According to Wall Street analysts MEDINET Co., Ltd.’s price is currently Overvalued.
Does MEDINET Co., Ltd. pay dividends?
MEDINET Co., Ltd. does not currently pay dividends.
What is MEDINET Co., Ltd.’s EPS estimate?
MEDINET Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDINET Co., Ltd. have?
MEDINET Co., Ltd. has 281,667,330 shares outstanding.
What happened to MEDINET Co., Ltd.’s price movement after its last earnings report?
MEDINET Co., Ltd. reported an EPS of -¥0.78 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MEDINET Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2370
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MEDINET Co., Ltd.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
Technical Analysis
Linical Co., Ltd.
―
Trans Genic Inc.
―
Soiken Holdings Inc.
―
―
PRISM BioLab Co. LTD
―